Impact of Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study

被引：0

作者：

Kumada, Naotaka ^{[1
,2
]}

Iinuma, Koji ^{[1
]}

Kubota, Yasuaki ^{[3
]}

Takagi, Kimiaki ^{[4
]}

Nakano, Masahiro ^{[5
]}

Ishida, Takashi ^{[6
]}

Yokoi, Shigeaki ^{[7
]}

Sugino, Fumiya ^{[1
]}

Kawase, Makoto ^{[1
]}

Takeuchi, Shinichi ^{[1
]}

Kawase, Kota ^{[1
]}

Kato, Daiki ^{[1
]}

Takai, Manabu ^{[1
]}

Tobisawa, Yuki ^{[1
]}

Ito, Takayasu ^{[8
]}

Nakane, Keita ^{[1
]}

Koie, Takuya ^{[1
]}

机构：

[1] Gifu Univ, Grad Sch Med, Dept Urol, Yanagido 1-1, Gifu 5011194, Japan

[2] Matsunami Gen Hosp, Dept Urol, 185-1 Kasamatsucho, Gifu 5016062, Japan

[3] Toyota Mem Hosp, Dept Urol, 1-1 Heiwacho, Toyota 4718513, Japan

[4] Daiyukai Hosp, Dept Urol, 1-9-9 Sakura, Ichinomiya 4918551, Japan

[5] Gifu Prefectural Gen Med Ctr, Dept Urol, 4-6-1 Noisiki, Gifu 5008717, Japan

[6] Gifu Municipal Hosp, Dept Urol, 7-1 Kashimacho, Gifu 5008513, Japan

[7] Cent Japan Int Med Ctr, Dept Urol, Minokamo 5058510, Japan

[8] Gifu Univ, Grad Sch Med, Ctr Clin Training & Career Dev, Gifu 5011194, Japan

来源：

DISEASES | 2024年 / 12卷 / 06期

基金：

日本学术振兴会;

关键词：

metastatic renal cell carcinoma; cytoreductive nephrectomy; immune checkpoint inhibitors; targeted therapy; immune checkpoint inhibitors-based combination therapy; TARGETED THERAPY; PLANNED NEPHRECTOMY; SUNITINIB; EFFICACY; CRITERIA;

D O I：

10.3390/diseases12060122

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

In this study, we aimed to determine the utility of cytoreductive nephrectomy (CN) in real-world clinical practice and investigate whether CN contributes to improved oncological outcomes in patients with metastatic renal cell carcinoma (mRCC). This retrospective multicenter cohort study enrolled patients with mRCC who received systemic therapy at six institutions between May 2005 and May 2023. The patients were divided into those who did not undergo CN (Group I) and those who underwent CN (Group II). The primary endpoints were oncological outcomes, including cancer-specific survival (CSS) and progression-free survival (PFS). Altogether, 137 patients with mRCC were included in this study. The median CSS was 14 months in Group I and 32 months in Group II (p < 0.001). Additionally, the median PFS in Groups I and II was 5 and 13 months, respectively (p = 0.006). A multivariate analysis showed that CN was an independent prognostic factor for CSS and PFS. Hence, CN is a potential treatment modality that can improve oncological outcomes in patients with mRCC.

引用

页数：16

共 45 条

[41] Cancer statistics, 2022
Siegel, Rebecca L.
Miller, Kimberly D.
Fuchs, Hannah E.
Jemal, Ahmedin
[J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2022, 72 (01) : 7 - 33
[42] Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database
Singla, Nirmish
Hutchinson, Ryan C.
Ghandour, Rashed A.
Freifeld, Yuval
Fang, Dong
Sagalowsky, Arthur I.
Lotan, Yair
Bagrodia, Aditya
Margulis, Vitaly
Hammers, Hans J.
Woldu, Solomon L.
[J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (06) : 604.e9 - 604.e17
[43] Clinical Review on the Management of Metastatic Renal Cell Carcinoma
Tran, Jennifer
Ornstein, Moshe C.
[J]. JCO ONCOLOGY PRACTICE, 2022, 18 (03) : 187 - +
[44] The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis
Tully, Karl H.
Berg, Sebastian
Paciotti, Marco
Janisch, Florian
Reese, Stephen W.
Noldus, Joachim
Shariat, Shahrokh F.
Choueiri, Toni
Mueller, Guido
McGregor, Bradley
Chang, Steven L.
Trinh, Quoc-Dien
Mossanen, Matthew
[J]. CLINICAL GENITOURINARY CANCER, 2023, 21 (01) : 63 - 68
[45] Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma
Van Praet, Charles
Slots, Charlotte
Vasdev, Nikhil
Roney, Sylvie
Fonteyne, Valerie
Andras, Lulia
Albersen, Maarten
De Meerleer, Gert
Bex, Axel
Decaestecker, Karel
[J]. TURKISH JOURNAL OF UROLOGY, 2021, 47 : S79 - S84

← 1 2 3 4 5 →